Harbor Investment Advisory’s Sarepta Therapeutics SRPT Stock Holding History

Harbor Investment Advisory’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1	Closed	-$158	–	1289
2024 Q2	$158	Buy	+1	New	+$128	﹤0.01%	1218
2023 Q3	–	Sell	-135	Closed	-$15.5K	–	1330
2023 Q2	$15.5K	Hold	135	–	–	﹤0.01%	941
2023 Q1	$18.6K	Hold	135	–	–	﹤0.01%	924
2022 Q4	$17.5K	Hold	135	–	–	﹤0.01%	921
2022 Q3	$15K	Hold	135	–	–	﹤0.01%	969
2022 Q2	$10K	Hold	135	–	–	﹤0.01%	1037
2022 Q1	$11K	Hold	135	–	–	﹤0.01%	1042
2021 Q4	$12K	Sell	135 -30	-18%	-$2.56K	﹤0.01%	1029
2021 Q3	$15K	Buy	165 +100	+154%	+$7.7K	﹤0.01%	990
2021 Q2	$5K	Hold	65	–	–	﹤0.01%	1102
2021 Q1	$5K	Hold	65	–	–	﹤0.01%	1077
2020 Q4	$11K	Hold	65	–	–	﹤0.01%	920
2020 Q3	$9K	Hold	65	–	–	﹤0.01%	877
2020 Q2	$10K	Hold	65	–	–	﹤0.01%	790
2020 Q1	$6K	Hold	65	–	–	﹤0.01%	840
2019 Q4	$8K	Buy	+65	New	+$6.56K	﹤0.01%	667

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Harbor Investment Advisory's SRPT Position: Q3 2024 in Review

Harbor Investment Advisory sold out of Sarepta Therapeutics (SRPT) in Q3 2024, closing a stake of 1 share — an estimated $158 sold.

Harbor Investment Advisory first reported a position in SRPT in Q4 2019 and held it in 16 quarters. The position peaked at $18.6K in Q1 2023. 457 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

Harbor Investment Advisory reported no remaining Sarepta Therapeutics position as of Q3 2024 after selling out during the quarter.
Harbor Investment Advisory sold 1 Sarepta Therapeutics share in Q3 2024, an estimated $158.
Harbor Investment Advisory first reported a position in Sarepta Therapeutics in Q4 2019 and held it in 16 quarters.
Harbor Investment Advisory's Sarepta Therapeutics position peaked at $18.6K in Q1 2023.
457 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on Harbor Investment Advisory's 13F filing for Q3 2024, filed 4 Oct 2024.